Trading · Founded 1990 · www.evexialifecare.com · BSE 524444 · · ISIN INE313M01030
No Notes Added Yet
Business
Evexia Lifecare Ltd. is primarily engaged in the business of trading. The company acts as an intermediary, sourcing a diverse range of products from suppliers and selling them to customers across various industries. Its product portfolio includes, but is not limited to, cotton, agricultural products, ferrous & non-ferrous metals, chemicals, and industrial products. The core business model involves leveraging market knowledge and logistical efficiency to buy products at competitive prices and sell them at a margin, generating revenue from the price differential and trading volumes.
Revenue Mix
The company's revenue is derived from its broad trading activities across multiple product categories. Detailed segment-wise revenue breakdown (e.g., specific percentages from cotton, metals, chemicals) is typically not disclosed in public filings for companies of this nature. The revenue mix is dynamic and dependent on market demand and supply for the various commodities and industrial products it trades.
Industry
Evexia Lifecare operates in the highly fragmented and competitive trading sector in India. This industry is characterized by numerous players, ranging from small regional traders to large diversified conglomerates. Barriers to entry for basic trading operations are relatively low, but success requires strong capital, extensive networks, and efficient logistics. Given its current scale, Evexia Lifecare Ltd. positions itself as a diversified trader, competing with many smaller to medium-sized players, rather than being a dominant force in any specific commodity trading segment.
MOAT
Evexia Lifecare Ltd., as a general trading company of its size, does not appear to possess strong, durable competitive advantages typically associated with a "moat" (e.g., strong brand, proprietary technology, network effects, high switching costs). Any advantages it may have are likely operational:
Relationships: Established network of suppliers and buyers.
Sourcing & Logistics: Ability to source products cost-effectively and manage efficient supply chains.
Market Knowledge: Specific understanding of supply-demand dynamics and pricing in its traded categories.
These advantages, however, are often replicable by competitors and do not provide a sustained, hard-to-overcome moat.
Growth Drivers
Economic Growth: India's overall economic expansion and industrial growth will drive demand for various commodities and industrial products traded by the company.
Product Portfolio Expansion: Identifying and entering new, profitable product categories or niche markets.
Supply Chain Optimization: Enhancing sourcing capabilities and logistical efficiencies to reduce costs and improve margins.
Strategic Partnerships: Forging alliances with larger manufacturers, distributors, or international trading houses to increase volumes and reach.
Increased Trade Volumes: General increase in the demand and supply of commodities in its existing portfolio.
Risks
Commodity Price Volatility: Fluctuations in the prices of traded goods (cotton, metals, chemicals) can significantly impact inventory values and profit margins.
Intense Competition: The fragmented nature of the trading sector can lead to price wars and pressure on margins.
Supply Chain Disruptions: Issues in sourcing, transportation, or logistics (e.g., natural disasters, geopolitical events) can affect operations and profitability.
Credit Risk: Risk of default from counterparties, especially when extending credit to buyers.
Regulatory Changes: Changes in trade policies, tariffs, or import/export regulations can impact business operations and costs.
Working Capital Management: Efficient management of inventory and accounts receivable/payable is crucial for liquidity and profitability, and failure to do so poses a risk.
Management & Ownership
Evexia Lifecare Ltd. is a promoter-driven company. Promoters typically hold a significant stake, aligning their interests with the company's performance. For instance, Mr. Sandeep G Singh and Mr. Rahul Kumar Singh are associated with the management and promoter group. The quality of management is largely tied to the experience and reputation of these key individuals in the trading and commodity markets. The remaining ownership is held by public shareholders.
Outlook
Evexia Lifecare operates in a fundamental segment of the economy, facilitating trade in essential commodities and industrial goods. The company could benefit from sustained economic growth in India, which fuels demand across sectors. Its diversified product portfolio allows it to capture opportunities in various markets. However, the trading sector is inherently low-margin, highly competitive, and exposed to significant commodity price volatility and supply chain risks. Without a clear, sustainable competitive moat, its ability to achieve consistent, superior profitability and growth might be challenged. Its small scale also limits bargaining power and access to capital compared to larger trading houses. Future performance will largely depend on management's ability to efficiently manage inventory, mitigate price risks, optimize logistics, and cultivate strong supplier and customer relationships in a dynamic market environment.
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 7 | 25 | 21 | 27 | 22 | 24 | 22 | 26 | 25 | 31 |
| Other Income | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 7 | 26 | 21 | 27 | 22 | 24 | 22 | 26 | 26 | 31 |
| Total Expenditure | 7 | 22 | 21 | 26 | 22 | 22 | 21 | 26 | 25 | 30 |
| Operating Profit | -0 | 4 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Interest | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -0 | 3 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 |
| Provision for Tax | -0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | -0 | 3 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Adjustments | 0 | -0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | -0 |
| Profit After Adjustments | -0 | 3 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Adjusted Earnings Per Share | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1 | 34 | 178 | 74 | 105 | 100 | 107 | 76 | 70 | 56 | 87 | 104 |
| Other Income | 0 | 1 | 0 | 1 | 3 | 12 | 74 | 0 | 2 | 1 | 0 | 0 |
| Total Income | 1 | 34 | 178 | 75 | 109 | 112 | 181 | 76 | 71 | 57 | 87 | 105 |
| Total Expenditure | 1 | 34 | 176 | 74 | 106 | 107 | 179 | 73 | 69 | 54 | 85 | 102 |
| Operating Profit | 0 | 0 | 1 | 1 | 3 | 5 | 2 | 2 | 2 | 3 | 2 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 1 | 1 | 2 | 5 | 2 | 2 | 2 | 2 | 1 | 3 |
| Provision for Tax | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Profit After Tax | 0 | 0 | 1 | 0 | 2 | 3 | 1 | 1 | 1 | 1 | 0 | 1 |
| Adjustments | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 |
| Profit After Adjustments | 0 | 0 | 1 | 0 | 2 | 3 | 1 | 1 | 1 | 1 | 0 | 1 |
| Adjusted Earnings Per Share | 0 | 0 | 0 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 55% | 5% | -3% | 56% |
| Operating Profit CAGR | -33% | 0% | -17% | 0% |
| PAT CAGR | -100% | -100% | -100% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 3% | 8% | -21% | 2% |
| ROE Average | 0% | 1% | 1% | 1% |
| ROCE Average | 0% | 0% | 1% | 2% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 66 | 65 | 66 | 73 | 75 | 78 | 80 | 80 | 90 | 130 | 460 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 |
| Borrowings | 0 | 9 | 4 | 6 | 4 | 1 | 0 | 0 | 696 | 682 | 375 |
| Other Non-Current Liabilities | 3 | 0 | 111 | 114 | 97 | 83 | 10 | 15 | 15 | 0 | 0 |
| Total Current Liabilities | 5 | 37 | 38 | 15 | 48 | 61 | 52 | 32 | 47 | 64 | 60 |
| Total Liabilities | 74 | 112 | 219 | 208 | 224 | 224 | 142 | 127 | 848 | 875 | 894 |
| Fixed Assets | 2 | 2 | 2 | 9 | 9 | 9 | 9 | 9 | 11 | 11 | 11 |
| Other Non-Current Assets | 69 | 48 | 56 | 127 | 128 | 86 | 24 | 48 | 749 | 767 | 784 |
| Total Current Assets | 3 | 61 | 161 | 72 | 88 | 129 | 109 | 70 | 87 | 97 | 100 |
| Total Assets | 74 | 112 | 219 | 208 | 224 | 224 | 142 | 127 | 848 | 875 | 894 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | -0 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 2 | 0 | 1 |
| Cash Flow from Operating Activities | 4 | 11 | -116 | -12 | -0 | -3 | 2 | -6 | -3 | 17 | -4 |
| Cash Flow from Investing Activities | 0 | 2 | 1 | -6 | 0 | 1 | -2 | 8 | -697 | -17 | -16 |
| Cash Flow from Financing Activities | -4 | -12 | 113 | 18 | 0 | 2 | 1 | -1 | 699 | 1 | 20 |
| Net Cash Inflow / Outflow | 1 | 1 | -2 | -0 | 0 | -0 | 0 | 1 | -1 | 0 | -0 |
| Closing Cash & Cash Equivalent | 1 | 2 | -1 | 1 | 1 | 0 | 1 | 2 | 0 | 1 | 1 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0 | 0 | 0.01 | 0.01 | 0.03 | 0.06 | 0.02 | 0.01 | 0.01 | 0.02 | 0 |
| CEPS(Rs) | 0 | 0 | 0.02 | 0.01 | 0.03 | 0.06 | 0.02 | 0.02 | 0.02 | 0.03 | 0 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 1.05 | 1.06 | 1.06 | 1.06 | 1.09 | 1.15 | 1.17 | 1.17 | 1.25 | 1.72 | 2.3 |
| Core EBITDA Margin(%) | -8.29 | -0.31 | 0.72 | -0.48 | -0.85 | -6.29 | -67.74 | 3.2 | 0.84 | 3.25 | 1.94 |
| EBIT Margin(%) | 26.7 | 0.96 | 0.76 | 1 | 2.15 | 5.09 | 1.81 | 3.01 | 2.98 | 4.08 | 1.55 |
| Pre Tax Margin(%) | 24.04 | 0.8 | 0.75 | 0.98 | 2.13 | 4.88 | 1.8 | 2.88 | 2.2 | 3.43 | 1.06 |
| PAT Margin (%) | 16.4 | 0.48 | 0.5 | 0.65 | 1.48 | 3.46 | 1.2 | 1.14 | 0.96 | 2.45 | 0.48 |
| Cash Profit Margin (%) | 47.05 | 0.72 | 0.55 | 0.89 | 1.79 | 3.77 | 1.43 | 1.42 | 1.52 | 3.19 | 1.02 |
| ROA(%) | 0.16 | 0.18 | 0.54 | 0.23 | 0.72 | 1.55 | 0.7 | 0.64 | 0.14 | 0.16 | 0.05 |
| ROE(%) | 0.3 | 0.25 | 1.37 | 0.73 | 2.35 | 5.01 | 1.79 | 1.19 | 0.86 | 1.35 | 0.15 |
| ROCE(%) | 0.27 | 0.44 | 1.86 | 1.05 | 3.16 | 6.81 | 2.46 | 2.89 | 0.48 | 0.29 | 0.16 |
| Receivable days | 1053.69 | 127.5 | 165.88 | 429.9 | 159.71 | 228.23 | 195.07 | 147.04 | 122 | 397.25 | 382.44 |
| Inventory Days | 157.3 | 3.41 | 1.26 | 3.41 | 2.49 | 2.65 | 6.68 | 11.23 | 8.81 | 10.1 | 6.71 |
| Payable days | 179.26 | 193.02 | 73.2 | 124.62 | 102.29 | 169.8 | 251.59 | 145.42 | 160.19 | 340.48 | 265.28 |
| PER(x) | 630.43 | 324.44 | 183.87 | 203.32 | 163.05 | 148.26 | 708.94 | 205.71 | 119.85 | 127.6 | 1186.36 |
| Price/Book(x) | 1.03 | 0.82 | 2.51 | 1.49 | 3.78 | 7.22 | 12.59 | 2.45 | 1.31 | 1.42 | 1.14 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 114.28 | 1.84 | 0.94 | 1.4 | 2.44 | 5.2 | 8.58 | 2.42 | 11.68 | 15.18 | 9.98 |
| EV/Core EBITDA(x) | 187.45 | 153.5 | 117.01 | 112.92 | 99.66 | 96.32 | 420.67 | 73.52 | 329.94 | 314.94 | 475.6 |
| Net Sales Growth(%) | -16.61 | 5378.97 | 422.71 | -58.26 | 42.27 | -4.95 | 6.42 | -29.18 | -7.89 | -19.1 | 53.88 |
| EBIT Growth(%) | 108.77 | 86.76 | 317.22 | -45.28 | 205.71 | 125.22 | -62.11 | 17.72 | -9.07 | 10.96 | -41.44 |
| PAT Growth(%) | 52.48 | 54.06 | 444.63 | -46.11 | 224.11 | 121.73 | -63.03 | -32.79 | -22.66 | 106.87 | -70.09 |
| EPS Growth(%) | -78.82 | 54.2 | 443.86 | -46.11 | 222.97 | 122.63 | -63.07 | -32.37 | -2.86 | 41.18 | -88.54 |
| Debt/Equity(x) | 0.07 | 0.16 | 0.05 | 0.09 | 0.06 | 0.1 | 0.09 | 0.08 | 8.5 | 5.59 | 0.87 |
| Current Ratio(x) | 0.67 | 1.67 | 4.2 | 4.92 | 1.82 | 2.11 | 2.08 | 2.18 | 1.86 | 1.51 | 1.66 |
| Quick Ratio(x) | 0.63 | 1.66 | 4.18 | 4.88 | 1.8 | 2.1 | 2.02 | 2.14 | 1.82 | 1.5 | 1.63 |
| Interest Cover(x) | 10.05 | 5.95 | 64.08 | 40.06 | 130.22 | 24.43 | 162.5 | 22.6 | 3.83 | 6.29 | 3.15 |
| Total Debt/Mcap(x) | 0.07 | 0.2 | 0.02 | 0.06 | 0.02 | 0.01 | 0.01 | 0.03 | 6.51 | 3.93 | 0.76 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 9.26 | 6.29 | 5.87 | 3.49 | 3.49 | 3.49 | 3.36 | 3.49 | 3.36 | 3.36 |
| FII | 0 | 1.03 | 1.49 | 0.16 | 0.16 | 0 | 0.47 | 0.47 | 0.12 | 0 |
| DII | 0.26 | 0.18 | 0.17 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Public | 90.48 | 92.5 | 92.47 | 96.25 | 96.25 | 96.41 | 96.07 | 95.94 | 96.41 | 96.54 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 | 6.32 | 6.56 | 6.32 | 6.32 |
| FII | 0 | 1.07 | 1.67 | 0.3 | 0.3 | 0 | 0.88 | 0.88 | 0.23 | 0 |
| DII | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 |
| Public | 64.06 | 96.34 | 103.33 | 180.69 | 180.69 | 180.99 | 180.35 | 180.11 | 181 | 181.23 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 70.8 | 104.16 | 111.74 | 187.73 | 187.73 | 187.73 | 187.73 | 187.73 | 187.73 | 187.73 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +55% | +5% | -3% | +56% |
| Operating Profit CAGR | -33% | 0% | -17% | — |
| PAT CAGR | -100% | -100% | -100% | — |
| Share Price CAGR | +3% | +8% | -21% | +2% |
| ROE Average | 0% | +1% | +1% | +1% |
| ROCE Average | 0% | 0% | +1% | +2% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 9.26 | 6.29 | 5.87 | 3.49 | 3.49 | 3.49 | 3.36 | 3.49 | 3.36 | 3.36 |
| FII | 0 | 1.03 | 1.49 | 0.16 | 0.16 | 0 | 0.47 | 0.47 | 0.12 | 0 |
| DII | 0.26 | 0.18 | 0.17 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Public | 90.48 | 92.5 | 92.47 | 96.25 | 96.25 | 96.41 | 96.07 | 95.94 | 96.41 | 96.54 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 | 6.32 | 6.56 | 6.32 | 6.32 |
| FII | 0 | 1.07 | 1.67 | 0.3 | 0.3 | 0 | 0.88 | 0.88 | 0.23 | 0 |
| DII | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 |
| Public | 64.06 | 96.34 | 103.33 | 180.69 | 180.69 | 180.99 | 180.35 | 180.11 | 181 | 181.23 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 70.8 | 104.16 | 111.74 | 187.73 | 187.73 | 187.73 | 187.73 | 187.73 | 187.73 | 187.73 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.